Shares dropped 24.9% following the earnings release as investors were clearly disappointed by the cautious outlook and enrollment delays in critical clinical programs, which suggest a deceleration in near-term growth drivers despite solid revenue growth.

• Total revenue grew 21% year-over-year to $174 million, with U.S. transplant product revenue up 22% and OUS transplant revenue increasing 39%.
• Adjusted operating profit reached $18.1 million, or 10.4% of revenue, reflecting ongoing heavy investment in growth initiatives.
• Enrollment delays in the ENHANCE and DENOVO clinical programs due to competitive reactions have postponed anticipated contributions from these key cardiothoracic growth drivers.
• Introduction of the CHOPS device aims to address clinical trial enrollment challenges and expand the product portfolio, but regulatory clearance is still pending.
• Despite operational progress, the market reacted negatively, signaling concerns over near-term growth sustainability and cautious outlook from management.